The new kit uses Tasso+ collection technology and certified laboratory analysis to monitor 17 health markers, including blood sugar and lipid levels.
Noom, a behavior change company, announced the launch of its at-home Biomarkers Test Kit for members in the United States. The kit is designed to establish baseline labs and track improvements in markers such as HbA1c, ApoB, triglycerides, and hs-CRP over time, according to a company release.
The kit enables members to collect a blood sample at home using the Tasso+ device. Samples are analyzed by a Clinical Laboratory Improvement Amendments and College of American Pathologists certified lab, with results delivered through the Noom app within one week.
Biomarker Selection and Clinical Utility
The test includes 17 biomarker-based insights selected by the company’s clinical team to provide a view of cardiovascular health, metabolic health, hormone balance, inflammation, and vitamin levels. Specific markers include ApoB, Lp(a), LDL, HDL, triglycerides, HbA1c, Total T, estradiol, LH, DHEA-S, hs-CRP, vitamin D, and B12.
Noom states that the inclusion of Lp(a) testing is significant because it is a genetic cardiovascular risk factor. While the American College of Cardiology and the American Heart Association recommend adults be tested for Lp(a) at least once, the company notes that only 1 in 1,000 people have undergone the test.
“Most people know very little about their health until they become sick,” says Geoff Cook, CEO of Noom, in a release. “Now with biomarker testing a tap away for every Noom member, we can make good on our promise: health you can see, wellbeing you can feel—and with the simple at-home biomarker test, our GLP-1 members can see for themselves the improvement in their blood sugar and other key benefits.”
Addressing Metabolic Risk
The company cited data indicating that 1 in 3 adults in the United States has prediabetes, with 8 in 10 unaware of the condition. By offering at-home testing for HbA1c, the platform aims to provide a point of early intervention for metabolic dysfunction.
Early data from the company’s Proactive Health program, involving participants with a median body mass index (BMI) of 23.8, suggests that metabolic and cardiovascular risks can accumulate even in individuals with a healthy BMI. The test kit is intended to create a feedback loop for individuals on GLP-1 therapies or behavior change programs, which may support medication adherence and motivation.
The Biomarkers Test Kit is currently available to United States members for $125.
Photo caption: Biomarkers Test Kit
Photo credit: Noom
